Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer

Abstract

Background Triple-negative breast cancer (TNBC) affects young women and is the most aggressive subtype of breast cancer (BC). TNBCs disproportionally affect women of African-American (AA) descent compared to other ethnicities. We have identified DNA repair gene RAD51 as a poor prognosis marker in TNBC and its posttranscriptional regulation through microRNAs (miRNAs). This study aims to delineate the mechanisms leading to RAD51 upregulation and develop novel therapeutic combinations to effectively treat TNBCs and reduce disparity in clinical outcomes. Methods Analysis of TCGA data for BC cohorts using the UALCAN portal and PrognoScan identified the overexpression of RAD51 in TNBCs. miRNA sequencing identified significant downregulation of RAD51-targeting miRNAs miR-214-5P and miR-142-3P. RT-PCR assays were used to validate the levels of miRNAs and RAD51, and immunohistochemical and immunoblotting techniques were used similarly for RAD51 protein levels in TNBC tissues and cell lines. Luciferase assays were performed under the control of RAD51 3’-UTR to confirm that miR-214-5P regulates RAD51 expression. To examine the effect of miR-214-5P-mediated downregulation of RAD51 on homologous recombination (HR) in TNBC cells, Dr-GFP reporter assays were performed. To assess the levels of olaparib-induced DNA damage responses in miR-214-5P, transfected cells, immunoblots, and immunofluorescence assays were used. Furthermore, COMET assays were used to measure DNA lesions and colony assays were performed to assess the sensitivity of BRCA-proficient TNBC cells to olaparib. Results In-silico analysis identified upregulation of RAD51 as a poor prognostic marker in TNBCs. miRNA-seq data showed significant downregulation of miR-214-5P and miR-142-3P in TNBC cell lines derived from AA women compared to Caucasian-American (CA) women. miR-214-5P mimics downregulated RAD51 expression and induces HR deficiency as measured by Dr-GFP assays in these cell lines. Based on these results, we designed a combination treatment of miR-214-5P and olaparib in HR-proficient AA TNBC cell lines using clonogenic survival assays. The combination of miR-214-5P and olaparib showed synergistic lethality compared to individual treatments in these cell lines. Conclusions Our studies identified a novel epigenetic regulation of RAD51 in TNBCs by miR-214-5P suggesting a novel combination therapies involving miR-214-5P and olaparib to treat HR-proficient TNBCs and to reduce racial disparity in therapeutic outcomes.

Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis

“…[ 27 , 28 ] The development of robust biomarkers for treatment response prediction is essential, encompassing genetic, epigenetic, and proteomic markers to refine patient selection and tailor treatment strategies. [ 29 ] Additionally, cohort studies across diverse populations are crucial for addressing treatment disparities and improving outcomes. [ 30 , 31 ] Ultimately, advancing OC treatment requires a multi-faceted approach, integrating innovative therapies, precision oncology, and comprehensive patient studies to personalize and improve care for this complex condition.…”

The crosstalk between benign thyroid disease and breast cancer: A single center study

“…And these outcomes hints at potential mechanisms by which thyroid dysfunction might influence breast cancer, indicating potential mechanisms of TT3, TT4, FT3, FT4, TSH, TPOAb, and TgAb regulating the tumor microenvironment in breast cancer. [ 5 , 6 ]…”

“…The primary cause of recurrence is the spread of breast cancer cells, with triple-negative breast cancer cells being an aggressive and difficult-to-treat type of breast cancer associated with a poor prognosis. [ 6 – 8 ] Different changes in key genes and pathways are involved in the metastasis process of various types of breast cancer cell lines. Furthermore, deaths reported in previous studies can be attributed to drug resistance and breast cancer subtypes.…”

“…Furthermore, deaths reported in previous studies can be attributed to drug resistance and breast cancer subtypes. [ 6 , 9 , 10 ] Some studies suggest that benign thyroid disease may be involved in the progression of breast cancer. [ 7 ] Related information remains limit.…”

Comprehensive analysis of the oncogenic and immunological role of SPON2 in human tumors

“…There were results suggested that a novel combination of miR-214-5P and olaparib could be an effective therapy for BRCA-wild-type TNBCs and reduce racial disparities in TNBC outcomes. [ 44 ] SPON2 intervention can be further studied. Ming Wu et al(2023) found that SPON2 promotes the bone metastasis of lung adenocarcinoma via activation of the NF-κB signaling pathway.…”